Cargando…

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

BACKGROUND: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, You-Hyun, Lee, Chan-Hee, Lee, Jisoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2006
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890742/ https://www.ncbi.nlm.nih.gov/pubmed/16913436 http://dx.doi.org/10.3904/kjim.2006.21.2.89

Ejemplares similares

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Effect of fenofibrate on uric acid level in patients with gout
por: Jung, Ju-Yang, et al.
Publicado: (2018)

The Stiff Joint: Comparative Evaluation of Monotherapy and Combination Therapy With Urate Lowering Agents in Managing Acute Gout
por: Okobi, Okelue E, et al.
Publicado: (2023)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout
por: Ahn, Huijeong, et al.
Publicado: (2021)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

Effects of fenofibrate therapy on renal function in primary gout patients
por: Li, Xinde, et al.
Publicado: (2021)

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients
por: van de Laar, Celine Johanna, et al.
Publicado: (2022)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack
por: Lee, Jung Sun, et al.
Publicado: (2020)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
por: Gill, Iqbal, et al.
Publicado: (2020)

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
por: Do, Hyunsue, et al.
Publicado: (2023)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
por: Chung, Ting-Ting, et al.
Publicado: (2019)

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
por: Singh, Jasvinder A
Publicado: (2014)

Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis
por: Yin, Rulan, et al.
Publicado: (2018)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Clinical Image: In vivo urate spherulites in a patient with gout
por: Pirker, Ian, et al.
Publicado: (2021)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
por: Christiansen, Sara Nysom, et al.
Publicado: (2020)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Effects of multiple genetic loci on the pathogenesis from serum urate to gout
por: Dong, Zheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n5vcbi060jk1du5aqma5ndu4t8